ECSP20032082A - Anticuerpos específicos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos - Google Patents

Anticuerpos específicos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos

Info

Publication number
ECSP20032082A
ECSP20032082A ECSENADI202032082A ECDI202032082A ECSP20032082A EC SP20032082 A ECSP20032082 A EC SP20032082A EC SENADI202032082 A ECSENADI202032082 A EC SENADI202032082A EC DI202032082 A ECDI202032082 A EC DI202032082A EC SP20032082 A ECSP20032082 A EC SP20032082A
Authority
EC
Ecuador
Prior art keywords
ilt3
specific antibodies
immunoglobulin type
similar transcript
immunoglobulin
Prior art date
Application number
ECSENADI202032082A
Other languages
English (en)
Inventor
JUAN Veronica
Fayadat-Dilman Laurence
Mieczkowski Carl
E Brandish Philip
A Meehl Michael
Singh Latika
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ECSP20032082A publication Critical patent/ECSP20032082A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen anticuerpos monoclonales no promiscuos humanizados específicos para el transcrito similar a la inmunoglobulina tipo 3 (ILT3), también conocido como receptor de tipo inmunoglobulina de leucocitos de la subfamilia B miembro 4 (LILRB4).
ECSENADI202032082A 2017-11-17 2020-06-12 Anticuerpos específicos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos ECSP20032082A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762587604P 2017-11-17 2017-11-17
PCT/US2018/061165 WO2019099597A2 (en) 2017-11-17 2018-11-15 Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof

Publications (1)

Publication Number Publication Date
ECSP20032082A true ECSP20032082A (es) 2020-08-31

Family

ID=64572590

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202032082A ECSP20032082A (es) 2017-11-17 2020-06-12 Anticuerpos específicos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos

Country Status (26)

Country Link
US (6) US11111297B2 (es)
EP (1) EP3710479A2 (es)
JP (1) JP7194481B2 (es)
KR (1) KR102478433B1 (es)
CN (2) CN111712518B (es)
AR (1) AR113696A1 (es)
AU (1) AU2018367524B2 (es)
BR (1) BR112020009759A8 (es)
CA (1) CA3082409A1 (es)
CL (1) CL2020001240A1 (es)
CO (1) CO2020006405A2 (es)
CR (1) CR20200204A (es)
DO (1) DOP2020000074A (es)
EA (1) EA202091228A1 (es)
EC (1) ECSP20032082A (es)
GE (2) GEP20237565B (es)
IL (1) IL274574A (es)
JO (1) JOP20200131A1 (es)
MA (1) MA50900A (es)
MX (2) MX2020005128A (es)
NI (1) NI202000036A (es)
PE (1) PE20210475A1 (es)
PH (1) PH12020550890A1 (es)
SG (1) SG11202004426SA (es)
TW (1) TWI816715B (es)
WO (1) WO2019099597A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
MA50900A (fr) * 2017-11-17 2020-09-23 Merck Sharp & Dohme Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations
WO2021127200A1 (en) * 2019-12-19 2021-06-24 Ngm Biopharmaceuticals, Inc. Ilt3-binding agents and methods of use thereof
CA3181197A1 (en) 2020-05-01 2021-11-04 NGM Biopharmaceuticals, Inc Ilt-binding agents and methods of use thereof
KR20230158057A (ko) * 2021-03-19 2023-11-17 머크 샤프 앤드 돔 엘엘씨 항-ilt3 항체를 사용하여 암을 치료하는 방법
AU2022318734A1 (en) * 2021-07-28 2024-02-08 Merck Sharp & Dohme Llc Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
CN116082502A (zh) * 2021-11-08 2023-05-09 复旦大学 Galectin8与LILRB4结合的调节剂及其应用
WO2023140875A1 (en) * 2022-01-19 2023-07-27 Ngm Biopharmaceuticals, Inc. Uses of ilt3-binding agents
US20250206820A1 (en) 2022-03-29 2025-06-26 Ngm Biopharmaceuticals, Inc. Ilt3 and cd3 binding agents and methods of use thereof
AU2023258644A1 (en) 2022-04-25 2024-12-05 Biond Biologics Ltd. Anti-ilt3 antibodies and use thereof
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
CN114716553B (zh) * 2022-06-08 2022-08-23 北京科诺信诚科技有限公司 靶向人lilrb4的纳米抗体及其应用
CN119894934A (zh) 2023-05-18 2025-04-25 南京维立志博生物科技股份有限公司 结合lilrb4和cd3的抗体及其用途
WO2025062392A1 (en) 2023-09-20 2025-03-27 Biond Biologics Ltd. Anti-ilt3 blockade combinations
WO2025141589A1 (en) 2023-12-31 2025-07-03 Biond Biologics Ltd. Treatment of cancer with anti-ilt3 antibodies

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0042924B1 (en) 1980-06-30 1984-03-21 International Business Machines Corporation Data transfer apparatus
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
CA2352572C (en) 1998-12-01 2010-04-20 Abbvie Biotherapeutics Inc. Humanized antibodies to gamma-interferon
AU2002345878A1 (en) * 2001-06-25 2003-01-08 The Trustees Of Columbia University In The City Of New York Ilt3 and ilt4-related compositions and methods
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2391438A1 (en) 2002-05-01 2003-11-01 Procyon Biopharma Inc. Psp94 diagnostic reagents and assays
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US8207110B2 (en) * 2004-09-03 2012-06-26 The Trustees Of Columbia University In The City Of New York ITL3 polypeptides and uses thereof
ES2720160T3 (es) 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
EP1907001B1 (en) 2005-06-17 2015-07-15 Merck Sharp & Dohme Corp. Ilt3 binding molecules and uses therefor
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
MX2008007682A (es) * 2005-12-20 2008-10-23 Sbi Biotech Co Ltd Anticuerpo anti-ilt7.
WO2007089945A2 (en) 2006-02-02 2007-08-09 The Trustees Of Columbia University In The City Of New York Treating diseases by targeting silt3
CA2655903A1 (en) 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
GB0705775D0 (en) 2007-03-26 2007-05-02 Affitech As Product
JP5191537B2 (ja) 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP5933894B2 (ja) 2007-09-14 2016-06-15 アディマブ， エルエルシー 合理的に設計された、合成抗体ライブラリおよびその使用
EP2242773B1 (en) 2008-02-11 2017-06-14 Cure Tech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP2328920A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
CN101830978A (zh) * 2009-03-09 2010-09-15 中国科学院微生物研究所 一种人免疫球蛋白样受体突变体及其应用
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
MX341925B (es) 2010-03-29 2016-09-07 Zymeworks Inc Anticuerpos con funcion efectora suprimida o mejorada.
NZ602515A (en) 2010-04-16 2015-06-26 Transbio Ltd Proteins that bind pi16 and uses thereof
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
US9696312B2 (en) 2011-09-02 2017-07-04 The Trustees Of Columbia University In The City Of New York Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US20150174203A1 (en) 2012-05-30 2015-06-25 Icahn School Of Medicine At Mount Sinai Compositions And Methods For Modulating Pro-Inflammatory Immune Response
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
SG11201509566RA (en) 2013-05-20 2015-12-30 Genentech Inc Anti-transferrin receptor antibodies and methods of use
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
IL283834B (en) 2014-09-28 2022-07-01 Univ California Modulation of stimulatory and non-stimulatory myeloid cells
WO2016127427A1 (zh) 2015-02-15 2016-08-18 华为技术有限公司 电子设备外壳的加工方法、电子设备外壳及电子设备
AU2016229201B2 (en) 2015-03-06 2021-01-28 The Board Of Regents Of The University Of Texas System Anti-LILRB antibodies and their use in detecting and treating cancer
EP3325006A4 (en) 2015-07-17 2019-03-06 The Trustees of Columbia University in the City of New York METHOD FOR TREATING CD166-EXPRESSIVE CANCER
SG11201804178YA (en) 2015-11-18 2018-06-28 Merck Sharp & Dohme Pd1 and/or lag3 binders
SG10202101958YA (en) 2016-08-31 2021-03-30 Agency Science Tech & Res Methods for the identification, targeting and isolation of human dendritic cell (dc) precursors "pre-dc" and their uses thereof
EP3538141A4 (en) 2016-11-10 2020-07-15 Merck Sharp & Dohme Corp. LIGAND ILT3
MA47468A (fr) 2017-02-09 2019-12-18 Bluefin Biomedicine Inc Anticorps anti-ilt3 et conjugués anticorps-médicament
MA50900A (fr) * 2017-11-17 2020-09-23 Merck Sharp & Dohme Anticorps spécifiques du transcrit 3 de type immunoglobuline (ilt3) et leurs utilisations
KR20230158057A (ko) * 2021-03-19 2023-11-17 머크 샤프 앤드 돔 엘엘씨 항-ilt3 항체를 사용하여 암을 치료하는 방법
AU2022318734A1 (en) * 2021-07-28 2024-02-08 Merck Sharp & Dohme Llc Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
JP2024532762A (ja) * 2021-08-11 2024-09-10 オンコホスト リミテッド 患者応答の予測
WO2023159152A2 (en) * 2022-02-17 2023-08-24 Immune-Onc Therapeutics, Inc. Combination therapy of lilrb antagonist and pd-1/pd-l1 axis inhibitor
WO2023235699A1 (en) * 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof
US20260042835A1 (en) * 2022-07-28 2026-02-12 Merck Sharp & Dohme Llc Methods for treating chronic myelomonocytic leukemia with anti-ilt3 antibodies

Also Published As

Publication number Publication date
CN120058946A (zh) 2025-05-30
TWI816715B (zh) 2023-10-01
GEAP202315366A (en) 2023-07-25
US20190153093A1 (en) 2019-05-23
MX2025000940A (es) 2025-03-07
KR102478433B1 (ko) 2022-12-15
MX2020005128A (es) 2020-07-27
BR112020009759A8 (pt) 2023-01-31
AU2018367524A1 (en) 2020-06-11
TW201922786A (zh) 2019-06-16
KR20200083598A (ko) 2020-07-08
EP3710479A2 (en) 2020-09-23
MA50900A (fr) 2020-09-23
US12441792B2 (en) 2025-10-14
EA202091228A1 (ru) 2020-08-12
AR113696A1 (es) 2020-06-03
US20220010010A1 (en) 2022-01-13
US11111297B2 (en) 2021-09-07
US20220033497A1 (en) 2022-02-03
CN111712518B (zh) 2025-03-25
US20220025043A1 (en) 2022-01-27
DOP2020000074A (es) 2020-08-31
CO2020006405A2 (es) 2020-06-09
GEP20237565B (en) 2023-11-10
JOP20200131A1 (ar) 2020-05-28
WO2019099597A3 (en) 2019-06-13
IL274574A (en) 2020-06-30
US20220010011A1 (en) 2022-01-13
AU2018367524B2 (en) 2022-09-15
JP2021503280A (ja) 2021-02-12
BR112020009759A2 (pt) 2020-11-03
US20220025042A1 (en) 2022-01-27
JP7194481B2 (ja) 2022-12-22
NI202000036A (es) 2020-09-24
CR20200204A (es) 2020-06-18
CL2020001240A1 (es) 2020-12-18
SG11202004426SA (en) 2020-06-29
PE20210475A1 (es) 2021-03-08
CA3082409A1 (en) 2019-05-23
US12435133B2 (en) 2025-10-07
CN111712518A (zh) 2020-09-25
PH12020550890A1 (en) 2021-04-12
WO2019099597A2 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
ECSP20032082A (es) Anticuerpos específicos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos
BR112022010206A2 (pt) Receptores de antígeno quiméricos e usos dos mesmos
ZA202211577B (en) Multivalent and multispecific 41bb-binding fusion proteins
CY1125347T1 (el) Ειδικοι σε κλαουδινη-18.2 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων
CY1125008T1 (el) Χιμαιρικοι υποδοχεις αντιγονων που στοχευουν συζευγμενους με πρωτεϊνη g yποδοχεις και χρησεις αυτων
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
MX2021012720A (es) Celulas t de receptor de antigeno quimerico co-estimulador que toman como diana a il13r-alfa-2.
MX2020003132A (es) Anticuerpos anti-ctla4 y usos de los mismos.
MX2019011927A (es) Anticuerpos anti-ilt4 y fragmentos de union a antigeno.
CY1121539T1 (el) Ειδικοι για κλαυδiνη-6 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων
AR105767A1 (es) Proteínas de fusión de unión a gitr multivalentes y multiespecíficas
CL2019000628A1 (es) Anticuerpos anti-pd-1 y sus usos.
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
CO2017006740A2 (es) Anticuerpos anti–cd79b
MX385456B (es) Anticuerpos cd123 y conjugados de los mismos.
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
CY1123046T1 (el) Ζωα εκτος του ανθρωπου που εχουν ανθρωποποιημενους υποδοχεις fc-γ
IL284091A (en) Antibodies neutralize the type 2 immunoglobulin-like leukocyte receptor
CL2018002639A1 (es) Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn.
MX2023002379A (es) Proteinas de fusion de union a dr5 multivalentes y multiespecificas.
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
CL2018002898A1 (es) Nuevos anticuerpos anti-sirpa y sus aplicaciones terapéuticas.
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
EP3757133A4 (en) ISOLATED ANTIGENIC CHEMICAL RECEPTOR, MODIFIED T LYMPHOCYTE INCLUDING IT AND ASSOCIATED USE
MX373326B (es) Anticuerpo anti-netrina-1 novedoso.